453
Views
0
CrossRef citations to date
0
Altmetric
Glomerulonephritis and Immunologic Disorders

The transcription factor HMGB2 indirectly regulates APRIL expression and Gd-IgA1 production in patients with IgA nephropathy

, , , &
Article: 2338931 | Received 19 Dec 2023, Accepted 31 Mar 2024, Published online: 15 Apr 2024

References

  • Berthoux FC, Mohey H, Afiani A. Natural history of primary IgA nephropathy. Semin Nephrol. 2008;28(1):1–11. doi: 10.1016/j.semnephrol.2007.10.001.
  • Hassler JR. IgA nephropathy: a brief review. Semin Diagn Pathol. 2020;37(3):143–147. doi: 10.1053/j.semdp.2020.03.001.
  • Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–2414. doi: 10.1056/NEJMra1206793.
  • Chao JC, Wan XS, Engelsberg BN, et al. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin. Biochim Biophys Acta. 1996;1307(2):213–219. doi: 10.1016/0167-4781(96)00052-8.
  • Kropotov AV, Yau P, Bradbury P, et al. Nonhistone chromosome proteins HMG1 and HMG2 stabilize one of the sequence-specific complexes, formed on the promotor of human retroposons of the ALU-family of other nuclear proteins. Mol Gen Mikrobiol Virusol. 1997;(4):32–36.
  • Zhai Y, Qi Y, Long X, et al. Elevated hsa-miR-590-3p expression down-regulates HMGB2 expression and contributes to the severity of IgA nephropathy. J Cell Mol Med. 2019;23(11):7299–7309. doi: 10.1111/jcmm.14582.
  • Yu X-Q, Li M, Zhang H, et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet. 2011;44(2):178–182. doi: 10.1038/ng.1047.
  • Castigli E, Scott S, Dedeoglu F, et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA. 2004;101(11):3903–3908. doi: 10.1073/pnas.0307348101.
  • Makita Y, Suzuki H, Kano T, et al. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 2020;97(2):340–349. doi: 10.1016/j.kint.2019.08.022.
  • Zhai Y-L, Zhu L, Shi S-F, et al. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine. 2016;95(11):e3099. doi: 10.1097/MD.0000000000003099.
  • Fan Z, Beresford PJ, Zhang D, et al. HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A. Mol Cell Biol. 2002;22(8):2810–2820. doi: 10.1128/MCB.22.8.2810-2820.2002.
  • Küchler R, Schroeder BO, Jaeger SU, et al. Antimicrobial activity of high-mobility-group box 2: a new function to a well-known protein. Antimicrob Agents Chemother. 2013;57(10):4782–4793. doi: 10.1128/AAC.00805-13.
  • Sgarra R, Furlan C, Zammitti S, et al. Interaction proteomics of the HMGA chromatin architectural factors. Proteomics. 2008;8(22):4721–4732. doi: 10.1002/pmic.200800193.
  • Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–686. doi: 10.2215/CJN.07420716.
  • Selvaskandan H, Cheung CK, Muto M, et al. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019;23(5):577–588. doi: 10.1007/s10157-019-01700-1.
  • Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep. 2023;8(3):499–506. doi: 10.1016/j.ekir.2022.12.014.
  • Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012;8(4):195–202. doi: 10.1038/nrrheum.2011.222.
  • Davies JE, Apta BHR, Harper MT. Cross-reactivity of anti-HMGB1 antibodies for HMGB2. J Immunol Methods. 2018;456:72–76. doi: 10.1016/j.jim.2018.02.006.
  • Takaishi H, Kanai T, Nakazawa A, et al. Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype. J Gastroenterol. 2012;47(9):969–977. doi: 10.1007/s00535-012-0566-3.
  • Yamanaka Y, Faghihi MA, Magistri M, et al. Antisense RNA controls LRP1 sense transcript expression through interaction with a chromatin-associated protein, HMGB2. Cell Rep. 2015;11(6):967–976. doi: 10.1016/j.celrep.2015.04.011.
  • Stros M, Ozaki T, Bacikova A, et al. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human bax gene promoter. J Biol Chem. 2002;277(9):7157–7164. doi: 10.1074/jbc.M110233200.
  • Taniguchi N, Kawakami Y, Maruyama I, et al. HMGB proteins and arthritis. Hum Cell. 2018;31(1):1–9. doi: 10.1007/s13577-017-0182-x.
  • Wang Y, Hu L, Zheng Y, et al. HMGA1 in cancer: cancer classification by location. J Cell Mol Med. 2019;23(4):2293–2302. doi: 10.1111/jcmm.14082.
  • Shen Z, Wu J, Gao Z, et al. High mobility group at-hook 1 (HMGA1) is an important positive regulator of hepatitis B virus (HBV) that is reciprocally upregulated by HBV X protein. Nucleic Acids Res. 2022;50(4):2157–2171. doi: 10.1093/nar/gkac070.
  • Li L, Kim J-H, Lu W, et al. HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. Blood. 2022;139(18):2797–2815. doi: 10.1182/blood.2021013925.
  • Ullah MA, Mackay F. The BAFF-APRIL system in cancer. Cancers. 2023;15(6):1791. doi: 10.3390/cancers15061791.